# Treatment options for myelofibrosis
Treatment of myelofibrosis is aimed at symptom relief, slowing disease progression and improving quality of life. The approach depends on risk classification (low, intermediate or high risk), your age, overall health and how well your body has responded to previous treatments. In recent years, new options have emerged, particularly JAK inhibitors, which have changed the treatment landscape.
JAK inhibitors
ProveniIncluded in official guidelines, or approved by EMA or FDA
JAK inhibitors suppress certain proteins (Janus Kinase) that are overactive in myelofibrosis cells. They are considered an important treatment group for many patients with myelofibrosis.
Ruxolitinib was the first JAK inhibitor approved for myelofibrosis and remains a commonly used starting point. It helps relieve symptoms such as fatigue, sweating and abdominal pain and can make an enlarged spleen smaller. Many patients feel better with ruxolitinib, although not everyone benefits from it. Known side effects include anemia (low hemoglobin), lower numbers of white blood cells and platelets, abdominal pain and weight gain. The body may adapt to the drug over time, reducing its effect (resistance).
Fedratinib, pacritinib and momelotinib are later JAK inhibitors used as an alternative or in follow-up treatment, especially when ruxolitinib does not work well or is not well tolerated. Fedratinib may carry a risk of diarrhea. Momelotinib is being investigated as a possible first-line option for patients with low platelet counts, as this drug is targeted to affect platelets less than ruxolitinib. Pacritinib was specifically developed for patients with low platelet counts and may be better tolerated in this group.
With all JAK inhibitors, regular blood monitoring is necessary to detect anemia, infections and other abnormalities in time.
Selinexor in combination with JAK inhibitors
ResearchediPositive results in clinical studies, not yet standard treatment
Selinexor is a drug that blocks proteins that help tumor cells grow. Recent studies are examining selinexor in combination with ruxolitinib in JAK inhibitor-naive patients (patients who have not previously used JAK inhibitors). The combination shows promising results in reducing spleen size and improving blood values. Possible side effects of selinexor include nausea, vomiting, fatigue and weight loss. The precise role of this combination in the treatment schedule is still being determined.
Other cytostatic agents
ProveniIncluded in official guidelines, or approved by EMA or FDA
Ruxolitinib and similar JAK inhibitors have displaced many older chemotherapies, but in certain situations other drugs are still used:
- **Hydroxyurea** (cytotoxic agent) can be used for patients with high white blood cell counts or symptoms that do not respond well to JAK inhibitors. It works by inhibiting cell division. Side effects include anemia, infertility and risk of later transformation to acute leukemia.
- **Lenalidomide** is an immunomodulatory drug that is particularly helpful in myelofibrosis patients with certain genetic abnormalities (for example, del 5q). It can improve anemia. Known side effects are anemia, thrombosis (blood clots), nerve damage and infections.
- **Anagrelide** is sometimes used to control elevated platelet counts, especially in early stages or when JAK inhibitors cannot be used. It works directly on megakaryocytes (cells that make platelets). Side effects include headache, heart palpitations and diarrhea.
Allogeneic hematopoietic stem cell transplantation
ProveniIncluded in official guidelines, or approved by EMA or FDA
This is the only treatment that can potentially cure myelofibrosis, but it is also the most burdensome. With stem cell transplantation, you first receive chemotherapy (and sometimes radiation) to eliminate your own myelofibrosis cells, after which stem cells from a donor are introduced into your body. These donor stem cells grow into a new blood-forming and immune system.
Stem cell transplantation is mainly considered in younger patients (usually under 70 years of age) with high risk and a suitable donor. The risk of early death around the transplantation and of complications such as graft-versus-host disease (GvHD, where donor cells attack your own cells) is significant. Recent studies are investigating new conditioning regimens (such as combinations of low-dose melphalan, fludarabine and thiotepa) with alternative donors to reduce the burden.
Long-term outcomes are better than without transplantation in patients who survive the procedure, but many patients experience serious long-term effects from the treatment itself.
Supportive care
ProveniIncluded in official guidelines, or approved by EMA or FDA
These measures serve to relieve symptoms and complications:
- **Transfusions** of red blood cells for anaemia. Frequent transfusion can cause iron accumulation, which can lead to organ damage.
- **Platelet transfusions** when the platelet count is critically low and bleeding is threatened.
- **Growth factors** (such as G-CSF) can sometimes be used to lower infection risk, although this is done cautiously because stimulation of white blood cells can also accelerate disease progression.
- **Treatment of complications** such as gout (allopurinol or febuxostat), gout attacks and splanchnic thrombosis (clots in abdominal blood vessels).
- **Supplementation** of folic acid and vitamin B12 because the body uses more of these substances.
Experimental approaches in ongoing research
ExperimentaliOngoing in study setting, outcome still unknown
Various new agents are being investigated in clinical trials:
- **New JAK inhibitors** (such as fLonoltinib, gecacitinib and INCA035784) that may work more selectively on certain JAK proteins or be better tolerated by certain organs.
- **Thrombopoietin (TPO) receptor agonists**: these stimulate platelet production and are being investigated for their effect on myelofibrosis progression and symptoms.
- **Introduction of precision medicine**: more targeted treatment based on your individual genetic profile (for example, which mutations you have) is a subject of intensive research.
- **Combination studies**: combinations of different mechanisms (for example JAK inhibitors plus selinexor, or JAK inhibitors plus experimental immunological agents) are under investigation.
- **Treatment of extramedullary haematopoiesis**: when blood formation establishes itself outside the bone marrow in organs (for example liver and spleen), research is being conducted into how this can be targeted.
The research landscape is evolving rapidly, and what is experimental now may be proven or investigated within a few years.
Treatment of specific complications
ProveniIncluded in official guidelines, or approved by EMA or FDA
- **Thrombosis** (clots in blood vessels, including in abdominal organs): is treated with anticoagulants (blood thinners), although given cautiously due to the strong tendency for bleeding in myelofibrosis.
- **Transformation to acute leukaemia**: this is a serious complication. Treatment resembles acute leukaemia protocols (for example hypomethylating agents such as azacitidine, or chemotherapy), but prognosis is generally limited.
- **Infections**: are treated aggressively due to the higher risk from anaemia and low white blood cell counts.
What determines which treatment you receive?
The choice depends on:
- Your **risk classification** (low, intermediate-1, intermediate-2 or high), determined by disease factors and genetic abnormalities.
- Your **age and overall health**.
- Your **blood cell count**, especially platelets (some JAK inhibitors are riskier with very low counts).
- Whether you have **received previous treatments** and how you responded to them.
- Your **preference** and the burden you are willing to undertake.
- The availability of a **suitable donor** (for transplantation).
Your healthcare provider will discuss this with you and adjust it if necessary as your disease progresses.
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._